Evidence map›Paper›PMID 41553201›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2026

Hyperglycemia, receptor for advanced glycation end products, and small airways dysfunction in asthma.

Paula Sierra Salas, Dennis T Villareal, Vickram Tejwani, Amrit Koirala, Cristian Coarfa, Meredith C McCormack, Nicola A Hanania, Tianshi David Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paula Sierra SalasSection of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas.
Dennis T VillarealSection of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Houston, Texas; Center for Translational Research on Inflammatory Diseases, Michael DeBakey VA Medical Center, Houston, Texas.
Vickram TejwaniDepartment of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, Ohio; Department of Genome Sciences and Systems Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Amrit KoiralaCenter for Precision Environmental Health, Baylor College of Medicine, Houston, Texas.
Cristian CoarfaCenter for Precision Environmental Health, Baylor College of Medicine, Houston, Texas; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Meredith C McCormackDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.
Nicola A HananiaSection of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas.
Tianshi David WuSection of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas. Electronic address: david.wu@bcm.edu.

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
Translation CoreP2CES033415 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI Kirsten Anne Koehler · 2022 to 2026
$4.8M
Insulin Resistance, Pre-Diabetes, and Diabetes in Obesity-Associated AsthmaK23HL151669 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WU, TIANSHI DAVID · 2021 to 2025
$1.0M
Leukotriene B4 and IL-8 in alpha-1 heterozygotes (PI*MZ genotype)K23HL173570 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Vickram Tejwani · 2024 to 2026
$512k
NCI NIH HHS P30 CA125123NHLBI NIH HHS K23 HL151669NHLBI NIH HHS K23 HL173570NIEHS NIH HHS P2C ES033415
6 · The paper itself

Abstract

backgroundDiabetes and insulin resistance are associated with higher risk of asthma exacerbation and preserved ratio impaired spirometry (PRISm), but the pathophysiology is unclear. These conditions may cause small airways dysfunction (SAD), which is an under-recognized cause of PRISm.

objectiveTo determine whether insulin resistance and poor glucose control associate with SAD and to explore whether proteins prognostic of diabetes end-organ complications predict lung function abnormalities.

methodsWe recruited a prospective cohort of adults with physician-diagnosed asthma. Fasting insulin, glucose, hemoglobin A1c, and concentrations of 13 proteins prognostic of diabetes end-organ complications were measured. Static insulin resistance was calculated by the homeostatic model assessment of insulin resistance. Lung function was measured by spirometry, and SAD was assessed by impulse oscillometry.

resultsA total of 65 participants were recruited. Mean body mass index was 32.7 kg/m

conclusionHyperglycemia was associated with SAD and PRISm in asthma. Soluble receptor for advanced glycation end products may be a biomarker of hyperglycemia-associated lung dysfunction. Longitudinal study is necessary to validate biomarker relationships and understand structural and physiological consequences.

Indexed as

AsthmaHyperglycemiaReceptors, ImmunologicAdultBlood GlucoseFemaleGlycated HemoglobinHumansInsulin ResistanceMaleMiddle AgedProspective StudiesReceptor for Advanced Glycation End ProductsRespiratory Function TestsSpirometryBlood GlucoseGlycated HemoglobinReceptor for Advanced Glycation End ProductsReceptors, Immunologic

Identifiers

PMID41553201
PMCPMC12973237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.